Ignite Creation Date:
2024-05-06 @ 4:05 AM
Last Modification Date:
2024-10-26 @ 11:43 AM
Study NCT ID:
NCT02450903
Status:
COMPLETED
Last Update Posted:
2021-03-30
First Post:
2015-05-08
Brief Title:
LDK378 in Patients With ALK Positive NSCLC Previously Treated With Alectinib
Sponsor:
Novartis Pharmaceuticals
Organization:
Novartis
Study Overview
Official Title:
A Phase II Multi-center Open-label Single-Arm Study to Evaluate the Efficacy and Safety of Oral LDK378 Treatment for Patients With ALK-Positive Non-Small Cell Lung Cancer Previously Treated With Alectinib
Status:
COMPLETED
Status Verified Date:
2021-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This was a single-arm open-label multicenter phase II study to evaluate the efficacy and safety of the ALK inhibitor LDK378 when used as single agent in patients with ALK-rearranged stage IIIB or IV NSCLC previously treated with alectinib Treatment with LDK378 750 mg qd continued until the patient experienced disease progression as determined by the investigator according to RECIST 11 unacceptable toxicity that precluded further treatment pregnancy start of a new anticancer therapy discontinued treatment at the discretion of the patient or investigator lost to follow-up death or study was terminated by Sponsor
Detailed Description:
Study completed as per protocol Switched to commercial drug implies that after the primary and secondary objectives were achieved one patient continued the study treatment as they did not meet the progression disease or AE to be discontinued from the treatment But after the regulatory approval Novartis decided to close the study the 1 patient switched to commercially available drug
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None